What is AbbVie's market cap?

AbbVie (ABBV) has a market capitalization of $449.91B and trades on NYSE.

What is AbbVie's revenue and profitability?

AbbVie generated $62.8B in trailing twelve-month revenue with net income of $3.6B, representing a net margin of 5.8%. Gross margin stands at 70.7%, with free cash flow of $20.0B. These figures are based on the Q1 2026 filing.

Who are AbbVie's competitors?

AbbVie's key competitors include Pfizer, Johnson & Johnson, Amgen, and others. These companies compete in similar markets and product categories.

Who does AbbVie partner with?

AbbVie's notable partners include GSK, Eisai, Genmab.

What subsidiaries does AbbVie have?

AbbVie's subsidiaries include Allergan, ImmunoGen.

Where is AbbVie headquartered?

AbbVie is headquartered in United States of America and employs approximately 50,000 people. It has been publicly traded since 2012.

AbbVie

ABBV

AbbVie is a global, research-based biopharmaceutical company focused on developing and marketing advanced therapies for complex and serious diseases.

Market cap

$449.91B+34.6%

Revenue$62.8B+9.5%

Net income$3.6B-13.4%

Free cash flow$20.0B+29.9%

EPS (diluted)$2.03-13.6%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 29, 2026

Revenue$15.0BBeat by $284.6M EPS$2.65Beat by $0.06

Read the full report

Next report

Jul 31, 2026 (In 3 weeks)

Revenue estimate$16.8B

EPS estimate$3.79

Financials

Q1 2026

Income statement

See full

Revenue$15.0B+12.4%

Gross profit$10.8B+15.4%

Operating income$4.0B+6.9%

Net income$695.0M-46.0%

EPS (diluted)$0.39-45.8%

Balance sheet

See full

Cash & equivalents$9.4B+81.5%

Total equity-$6.7B-569%

Total assets$136.46B+0.2%

Cash flow

See full

Operating cash flow$3.8B+134%

CapEx$265.0M+12.8%

Free cash flow$3.6B+155%

Valuation & ratios

Valuation

See full

Market cap$449.91B+34.6%

P/E123.8×+34.2×

P/S7.2×+1.4×

Profitability

See full

Gross margin70.7%0.0pp

Operating margin24.4%—

Net margin5.8%-1.5pp

FCF margin31.8%+5.0pp

Returns & leverage

See full

Current ratio0.8×0.0×

Segments

By product

See full

Skyrizi$4.5B+30.9%

Rinvoq$2.1B+23.3%

All other$1.0B-18.2%

Botox Therapeutic$1.0B+16.5%

Vraylar$905.0M+18.3%

Competitors

By market cap

Eli Lilly$1.10T+57.5%

Johnson & Johnson$643.30B+71.9%

AbbVie$449.91B+33.5%

Cardinal Health$56.1B+45.2%

By revenue growth

Eli Lilly+47.4%

Cardinal Health+12.8%

McKesson+12.4%

AbbVie+9.5%

Amgen+9.1%

Johnson & Johnson+7.9%

Cencora+5.9%

Pfizer+1.4%

By net margin

Eli Lilly34.99%+12.3pp

Johnson & Johnson21.83%-2.6pp

Amgen20.96%+3.6pp

Pfizer15.65%+6.3pp

AbbVie5.79%-1.5pp

McKesson1.18%+0.3pp

Cardinal Health0.62%-0.1pp

Cencora0.599%+0.6pp

Profile

AbbVie is a global, research-based biopharmaceutical company focused on developing and marketing advanced therapies for complex and serious diseases. The company maintains leadership positions in several high-growth therapeutic areas including immunology, oncology, neuroscience, and aesthetics. Its value proposition is centered on clinical innovation and a diversified portfolio of proprietary medicines that address significant unmet medical needs.

Competitive position

A global leader in immunology and aesthetics with a dominant market share in biologic therapies, currently managing the transition of its legacy blockbuster portfolio toward newer growth assets.

GeographiesNorth America, European Union, Japan, China, Global

Customer segmentsHospitals, Physicians, Managed Care Providers, Government Agencies, Pharmacy Benefit Managers

Business modelResearch and Development, Manufacturing, Direct-to-Consumer Marketing, B2B Distribution

SuppliersRaw material suppliers, Specialized chemical manufacturers, Clinical research organizations, Biologics infrastructure providers

CustomersWholesale pharmaceutical distributors, Retail pharmacies, Hospitals and health systems, Government health programs (Medicaid, VA), Specialty clinics

CountryUnited States of America

Listed2012

Employees50.0K

CEORobert A. Michael

SectorHealthcare

IndustryDrug Manufacturers - General

Websiteabbvieinvestor.com

FilingsSEC EDGAR

Ask your AI about AbbVie.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AbbVie's market cap?: AbbVie (ABBV) has a market capitalization of $449.91B and trades on NYSE.
What is AbbVie's revenue and profitability?: AbbVie generated $62.8B in trailing twelve-month revenue with net income of $3.6B, representing a net margin of 5.8%. Gross margin stands at 70.7%, with free cash flow of $20.0B. These figures are based on the Q1 2026 filing.
Who are AbbVie's competitors?: AbbVie's key competitors include Pfizer, Johnson & Johnson, Amgen, and others. These companies compete in similar markets and product categories.
Who does AbbVie partner with?: AbbVie's notable partners include GSK, Eisai, Genmab.
What subsidiaries does AbbVie have?: AbbVie's subsidiaries include Allergan, ImmunoGen.
Where is AbbVie headquartered?: AbbVie is headquartered in United States of America and employs approximately 50,000 people. It has been publicly traded since 2012.